Human luteinizing hormone-human chorionic gonadotropin receptor (Human LH/hCG receptor)

Abstract: Disclosed are (1) a human luteinizing hormone-human chorionic gonadotropin receptor protein, (2) a DNA comprising a cDNA segment coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein, (3) a transformant carrying a DNA comprising a cDNA segment coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein, and (4) a method for preparing a human luteinizing hormone-human chorionic gonadotropin receptor protein which comprises cultivating the transformant described in (3), accumulating a protein in a culture broth, and collecting the same, whereby the structure and properties of the receptor protein are made clear and the mass production thereof by recombinant technology is pioneered.

Description: BACKGROUND OF THE INVENTION The present invention relates to a DNA containing a cDNA sequence coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein (human LH/hCG receptor protein), the human LH/hCG receptor protein, and a method for preparing the protein. The human luteinizing hormone-human chorionic gonadotropin receptor proteins (human LH/hCG receptor proteins) exist in the Leydig cells in the testis, the theca cells in the ovary, the granulosa cells, the corpus luteum cells and the interstitial cells, and play a central role in reproductive physiology. In the male and the female who is not pregnant, the LH/hCG receptor proteins are acted on only by luteinizing hormone (LH) produced in the anterior lobe of the pituitary and secreted therefrom. In the pregnant female, however, the LH/hCG receptor proteins in the ovary are acted on also by human chorionic gonadotropin (hCG) produced by the placenta. LH and hCG are members of a family of glycoprotein hormones also including thyroid-stimulating hormone (TSH) and follicle-stimulating hormone (FSH). Each of these four hormones has a molecular weight of 28 to 38 kD, and is a heterodimer glycoprotein in which a specific β subunit relating to receptor binding specificity is bound to an α subunit common to these hormones. The glycosyl moiety of these hormones seem to play an important role in signal introduction. The β subunits of both LH and hCG are closely related to each other in their structure. These two hormones bind to the same receptor and induce the same biological reaction. The similarity between these glycoprotein hormones and the action by these hormones on the receptors to enhance the activity of adenylate cyclase mediated by G-proteins reveal that these receptors have a common mechanism of hormone-induced activation. The increases of adenosine 3',5'-monophosphate (cyclic AMP) necessarily lead to the synthesis and secretion of steroids. A family of G protein-coupled receptors are identified whose members are characterized by the common structural feature of having seven transmembrane domains which are known to relate to the signal introduction and binding to small ligands. On the other hand, TSH and FSH receptors have been compared with the LH/hCG receptors. As a result, of the G protein-coupled receptors, these receptors of the pituitary glycoprotein hormones are characterized by the presence of a large glycosylated domain which is grafted onto a structure containing seven transmembrane segments and putatively considered to be positioned on the outside of cells. The structure of the LH/hCG receptors have not been elucidated so well yet, because the receptors are present in very low amounts and sensitive to proteolysis. For rat and porcine LH/hCG receptors, however, complementary DNAs (cDNAs) of these receptors are isolated and the amino acid sequences thereof are also deduced from these DNAs [Science 245, 494 (1989) for rats and Science 245, 525 (1989) for pigs]. For the rat and porcine LH/hCG receptors, the structure thereof has been thus elucidated. For the human LH/hCG receptors, however, the structure thereof is not revealed. Considering to use the human LH/hCG receptors as therapeutic drugs and analytical reagents for humans, it is necessary to make clear the structure and properties thereof. SUMMARY OF THE INVENTION The present inventors have recognized that important contributions will be made to future studies and medical treatments, if an human LH/hCG receptor can be collected from humans and further prepared by recombinant technology. As a result, the present inventors have first succeeded in cloning cDNA coding for a human LH/hCG receptor from a cDNA library of the human ovary by using the complementary DNA of a rat LH/hCG receptor as a probe, and in elucidating a complete nucleotide sequence thereof. Further, the present inventors have also succeeded in elucidating an amino acid sequence of the human LH/hCG receptor from this cDNA and in pioneering the mass production of this receptor by recombinant technology. This receptor is very similar to the rat and porcine receptors. However, the differences are such that each receptor can be recognized to be a different one. In accordance with the present invention, there are provided (1) a human luteinizing hormone-human chorionic gonadotropin receptor protein, which protein has an amino acid sequence represented by the 1st to 699th amino acid residues of SEQ ID NO:1 or an amino acid sequence lacking the 227th to 289th amino acid residues therefrom or an amino acid sequence represented by the 26th to 699th amino acid residues of SEQ ID NO:1 or an amino acid sequence lacking the 227th to 289th amino acid residues therefrom; (2) a DNA comprising a cDNA sequence coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein as defined in (1) above; (3) a transformant carrying a DNA as defined in (2) above; (4) a method for preparing a human luteinizing hormone-human chorionic gonadotropin receptor protein as defined in (1) above, which method comprises cultivating a transformant carrying a DNA as defined in (2) above, accumulating the protein in a culture broth, and collecting the same; (5) a pharmaceutical composition comprising an effective amount of a human luteinizing hormone-human chorionic gonadotropin receptor protein as defined in (1) above and a pharmaceutically acceptable carrier or vehicle; and (6) the use of a protein as defined in (1) above for preparing a medicament for the diagnosis and management of ovarian and testicular diseases. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows a nucleotide sequence of a human LH/hCG receptor protein DNA segment, as well as an amino acid sequence deduced therefrom; and Fig. 2 shows the amino acid sequence of the human LH/hCG receptor protein and amino acid sequences of other known LH/hCG receptor proteins and proteins having similar action, comparing them to one another. Figs. 3 and 4 are SDS-PAGE diagrams which show expression of HLHR protein in Example 2. Fig. 5 is a graph which shows that the protein obtained according to the present invention has response ability to hCG. DESCRIPTION OF THE PREFERRED EMBODIMENTS The present inventors cloned two kinds of cDNAs of the human luteinizing hormone-human chorionic gonadotropin receptor protein to deduce a primary structure of the complete protein (Fig. 1). The first methionine in this sequence is considered to be an initiator codon. This is followed by an amino acid sequence having the characteristics of a signal peptide with a cleavage site present. A possible model for construction of the protein was suggested by hydropathy analysis and comparison with the rat and porcine LH/hCG receptors (Fig. 2). A putative extracellular domain of 335 amino acids precedes a region of 267 amino acids that displays seven possible transmembrane segments (regions surrounded by rectangles in Fig. 2 and labeled I to II). There is a 72 amino acid COOH-terminal intracellular domain. The mature protein may consist of 674 amino acids (75632 daltons). In addition to this protein, 25 signal peptides (the 1st to 25th amino acids in Figs. 1 and 2) exist. However, these peptides are cut off during synthesis of the receptor, and therefore the mature protein of the receptor is considered to consist of 674 amino acids (the 26th to 699th amino acids). At the primary structure level, this extracellular domain has about 85% homology with the rat and porcine LH/hCG receptors and 45% homology with TSH and FSH receptors (in Fig. 2, hLH/hCGR indicates the human LH/hCG receptor; rLH/hCGR indicates the rat LH/hCG receptor; pLH/hCGR indicates the porcine LH/hCG receptor; hTSHR indicates the human TSH receptor [Biochem. Biophys. Res. Comm. 166, 394 (1990)]; and rFSHR indicates the rat FSH receptor [Mol. Endo. 4 , 525 (1990)]). Six potential glycosylation sites are found in the putative extracellular domain (underlined portions in Fig. 1). Clusters of cysteine residues are present in the NH 2 -terminal portion and between the putative extracellular and transmembrane domains of the above protein. Since these cysteine residues are conserved in the LH, FSH and TSH receptors, while not wishing to be bound by theory, it may be said that the formation of disulfide bonds is crucial for the conformational integrity of the large extracellular domains of glycoprotein hormone receptors. The domain considered to contain the transmembrane domains has about 90% homology with the rat and porcine LH/hCG receptors, and 70% homology with the TSH and FSH receptors. Serine and threonine residues are found with high frequency in a putative intercellular domain having three sites which is possibly phosphorylated by protein kinase C (Fig. 1). Since the phosphorylation by protein kinase specific to the receptors play a role in agonist specific decoupling of adrenergic receptors from the G proteins, it is important to know whether the phosphorylation in at least one of these sites causes any functional changes of the LH/hCG receptors. In the present invention, in addition to a clone having a large open reading frame, a clone coding for a shorter protein was obtained. The large clone is the 1st to 699th amino acid residues in Fiq. 1 (SEQ ID N0:1), the truncated type is one from which a region of the 227th to 289th amino acid residues surrounded by a rectangle is lacking. This pattern suggests that the cleavage mechanism necessary to complete mRNA has selectivity. These results are very similar to the data of the porcine LH/hCG receptor. The role of this truncated type receptor is not understood well, and it is not known either whether this LH/hCG receptor is physiologically active as a monomer or an oligomer. In humans, this TSH receptor can be a target of autoimmune reaction which leads to hyper- or hypo-stimulation of the thyroid gland by autoantibodies in Grave's disease and idiopathic myxedema. Thus, not only for contributions to diagnosis and management of ovarian diseases, but also for better understanding of ovarian physiology, it is necessary to isolate the human LH/hCG receptor and to know its characteristics. Fig. 2 shows the amino acid sequence of the novel human luteinizing hormone-human chorionic gonadotropin receptor protein obtained in the present invention, and compares this amino acid sequence with the amino acid sequences of the rat and porcine luteinizing hormone-human chorionic gonadotropin receptor proteins and the FSH and TSH receptors having similar action. The same amino acid residue as appears in the human luteinizing hormone-human chorionic gonadotropin receptor protein of the present invention, is represented by ".", and an amino acid residue different from that of the human LH/hCG receptor is represented by the appropriate symbol as defined herein. CONSENSUS shown in Fig. 2 indicates amino acid residues common to all the glycoproteins shown in Fig. 2. The illustration of CONSENSUS results in introduction of lacking portions "-" into the formulae in Fig. 2. Accordingly, the number representing the amino acids is counted excluding these lacking portions. For a DNA sequence, the DNA coding for the human LH/hCG receptor of the present invention contains the nucleotide sequence shown in Fig. 1 or a portion thereof. As the cDNA coding for the human LH/hCG receptor of the present invention, any cDNA may be used as long as it contains a nucleotide sequence coding for an amino acid sequence of the human LH/hCG receptor. For example, DNA containing the nucleotide sequence shown in Fig. 1 or a portion thereof is preferably used. The nucleotide sequence shown in Fig. 1 is an example of cDNA sequences coding for the human LH/hCG receptor obtained in the present invention. In the present invention, for example, an expression vector having the cDNA containing the nucleotide sequence coding for the human LH/hCG receptor can be prepared by the following process: (a) Messenger RNA (mRNA) is isolated from human LH/hCG receptor-producing cells. (b) Single stranded complementary DNA (cDNA) is synthesized from the mRNA, followed by synthesis of double stranded DNA. (c) The complementary DNA is introduced into a phage or a plasmid. (d) Host cells are transformed with the recombinant phage or plasmid thus obtained. (e) After cultivation of the transformants thus obtained, plasmids or phages containing the desired DNA are isolated from the transformants by an appropriate method such as hybridization with a DNA probe coding for a portion of the rat LH/hCG receptor or immunoassay using an anti-LH/hCG receptor antibody. (f) The desired cloned DNA is cut out from the recombinant DNA. (g) The cloned DNA or a portion thereof is ligated downstream from a promoter in the expression vector. The mRNA coding for the human LH/hCG receptor can be obtained from various human LH/hCG receptor-producing cells, for example, germ cells such as the Leydig cells in the testis, the capsular cells in the ovary, the granulosa cells, the corpus luteum cells and the interstitial cells. Methods for preparing the mRNA from the human LH/hCG receptor-producing cells include the guanidine thiocyanate method [J. M. Chirgwin et al., Biochemistry 18 , 5294 (1979)]. Using the mRNA thus obtained as a template, cDNA is synthesized by use of reverse transcriptase, for example, in accordance with the method of H. Okayama et al. [ Molecular and Cellular Biology 2 , 161 (1979); and ibid. 3 , 280 (1983)]. The cDNA thus obtained is introduced into the plasmid. The plasmids into which the cDNA may be introduced include, for example, pBR322 [ Gene 2 , 95 (1977)], pBR325 [Gene 4, 121 (1978)], pUC12 [ Gene 19 , 259 (1982)] and pUC13 [Gene 19 , 259, each derived from Escherichia coli, and pUB110 derived from Bacillus subtilis [Biochemical and Biophysical Research Communication 112 , 678 (1983)]. However, any other plasmid can be used as long as it is replicable and viable in the host cell. Examples of the phage vectors into which the cDNA may be introduced include λgt11 [R. Young and R. Davis, Proc. Natl. Acad. Sci. U.S.A. 80 , 1194 (1983)]. However, any other phage vector can be used as long as it is viable in the host cell. Methods for introducing the cDNA into the plasmid include, for example, the method described in T. Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory, p.239 (1982). Methods for introducing the cDNA into the phage vector include, for example, the method of T. V. Hyunh et al. [ DNA Cloning , A Practical Approach 1 , 49 (1985)]. The plasmid thus obtained is introduced into an appropriate host cell such as Escherichia and Bacillus. Examples of Escherichia described above include E. coli K12DH1 [ Proc. Natl. Acad. Sci. U.S.A. 60 , 160 (1968)], M103 [Nucleic Acids Research 9, 309 (1981)], JA221 [Journal of Molecular Biology 120, 517 (1978)], HB101 [ Journal of Molecular Biology 41 , 459 (1969)] and C600 [ Genetics 39 , 440 (1954)]. Examples of Bacillus described above include Bacillus subtilis MI114 [ Gene 24 , 255 (1983)] and 207-21 [ Journal of Biochemistry 95 , 87 (1984)]. Methods for transforming the host cell with the plasmid include, for example, the calcium chloride method or the calcium chloride/rubidium chloride method described in T. Maniatis et al., Molecular Cloning, Cold Spring harbor Laboratory, p.249 (1982). When the phage vector is used, for example, it can be transduced into proliferated E. coli, using the in vitro packaging method. Human LH/hCG receptor-cDNA libraries containing human LH/hCG receptor cDNA can be purchased from the market, though obtainable by the methods described above. For example, a cDNA library of the LH/CG receptor is available from Clontech Laboratories, Inc., U.S.A. Methods for cloning human LH/hCG receptor cDNA from the human DNA library include, for example, the plaque hybridization method using phage vector λcharon 28A and rat LH/hCG receptor cDNA as a probe [T. Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory, (1982)]. The human LH/hCG receptor cDNA thus cloned may be subcloned, for example, in pBR322, pUC12, pUC13, pUC18, pUC19, pUC118 and pUC119 to obtain the human LH/hCG receptor cDNA, if necessary. The nucleotide sequence of the cDNA thus obtained is determined, for example, by the Maxam-Gilbert method [A. M. Maxam and W. Gilbert, Proc. Natl. Acad. Sci. U.S.A. 74, 560 (1977)] or the dideoxy method [J. Messing et al., Nucleic Acids Research 9 , 309 (1981)], and the existence of the human LH/hCG receptor cDNA is confirmed in comparison with the known amino acid sequence. As described above, the cDNA coding for the human LH/hCG receptor protein is obtained. Fig. 1 shows the nucleotide sequence of the cDNA determined by the dideoxy method for the cDNA coding for the human LH/hCG receptor protein obtained in Example 1 described below, and the amino acid sequence proved from that nucleotide sequence. The cDNA coding for the human LH/hCG receptor protein cloned as described above can be used as is, or after digestion with a restriction enzyme if desired, depending on the intended use. A region intended to be expressed is cut out from the cloned cDNA and ligated downstream from a promoter in a vehicle (vector) suitable for expression, whereby the expression vector can be obtained. The cDNA has ATG as a translation initiating codon at the 5'-terminus thereof and may have TAA, TGA or TAG as a translation terminating codon at the 3'-terminus. The translation initiating codon and translation terminating codon may be added by use of an appropriate synthetic cDNA adaptor. A promoter is further ligated upstream therefrom for the purpose of expressing the cDNA. Examples of the vectors include the above plasmids derived from E. coli such as pBR322, pBR325, pUC12 and pUC13, the plasmids derived from Bacillus subtilis such as pUB110, pTP5 and pC194, plasmids derived from yeast such as pSH19 and pSH15, bacteriophages such as λ phage, and animal viruses such as retroviruses and vaccinia viruses. As the promoter used in the present invention, any promoter is available as long as it is suitable for expression in the host cell selected for the gene expression. When the host cell used for transformation is Escherichia, it is preferable that a trp promoter, a lac promoter, a recA promoter, a λP L promoter or a lpp promoter is used. When the host cell is Bacillus, it is preferable that a SPO1 promoter, a SPO2 promoter or a penP promoter is used. When the host cell is yeast, it is preferable that a PHO5 promoter, a PGK promoter, a GAP promoter or an ADH promoter is used. In particular, it is preferable that the host cell is Escherichia and the promoter is the trp promoter or the λP L promoter. When the host cell is an animal cell, a SV-40 derived promoter, a retrovirus promoter, a metallothionein promoter or a heat shock promoter is usable. An enhancer is also effectively used for expression. Using a vector containing the cDNA coding for the mature peptide of the human LH/hCG receptor protein thus constructed, transformants are prepared. The host cells include, for example, Escherichia, Bacillus, yeast and animal cells. Specific examples of the above Escherichia and Bacillus include strains similar to those described above. Examples of the above yeast include Saccharomyces cerevisiae AH22, AH22R - , NA87-11A and DKD-5D. Examples of the animal cells include monkey cell COS-7, Vero, Chinese hamster cell (CHO), mouse L cell and human FL cell. The transformation of the above Escherichia is carried out, for example, according to the method described in Proc. Natl. Acad. Sci. U.S.A. 69, 2110 (1972) or Gene 17, 107 (1982). The transformation of the above Bacillus is conducted, for example, according to the method described in Molecular & General Genetics 168, 111 (1979). The transformation of the yeast is carried out, for example, according to the method described in Proc. Natl. Acad. Sci. U.S.A. 75, 1929 (1978). The transformation of the animal cells is carried out, for example, according to the method described in Virology 52 , 456 (1973). Thus, transformants are obtained which have been transformed with the expression vector containing the cDNA coding for the human LH/hCG receptor. When bacterial transformants are cultured, a liquid medium is particularly suitable as a medium used for culture. Carbon sources, nitrogen sources, inorganic compounds and others necessary for growth of the transformants are contained therein. Examples of the carbon sources include glucose, dextrin, soluble starch and sucrose. Examples of the nitrogen sources include inorganic or organic materials such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extracts, soybean meal and potato extract solution. The inorganic compounds include, for example, calcium chloride, sodium dihydrogenphosphate and magnesium chloride. Yeast, vitamins, growth promoting factors and so on may be further added thereto. The pH of the medium is preferably 5 to 8. As the medium used for cultivation of Escherichia, for example, M9 medium containing glucose and Casamino Acids (Miller, Journal of Experiments in Molecular Genetics 431-433, Cold Spring Harbor Laboratory, New York, 1972) is preferably used. In order to make the promoter act efficiently, a drug such as 3-β-indolylacrylic acid may be added thereto if necessary. When the host cell is Escherichia, the cultivation is usually carried out at 15 to 43°C for 3 to 24 hours, with aeration or agitation if necessary. When the host cell is Bacillus, the cultivation is usually carried out at 30 to 40°C for 6 to 24 hours, with aeration or agitation if necessary. When yeast transformants are cultured, for example, Burkholder minimum medium [K. L. Bostian et al., Proc. Natl. Acad. Sci. U.S.A. 77, 4505 (1980)] is used as the medium. The pH of the medium is preferably adjusted to 5 to 8. The cultivation is usually carried out at 20 to 35°C for 24 to 72 hours, with aeration or agitation if necessary. When animal cell transformants are cultured, examples of the mediums include MEM medium containing 5 to 20% fetal calf serum [Science 122, 501 (1952)], DMEM medium [ Virology 8 , 396 (1959)], RPMI1640 medium (The Journal of the American Medical Association 199, 519 (1967)] and 199 medium [Proceeding of the Society for the Biological Medicine 73 , 1 (1950). The pH is preferably 6 to 8. The cultivation is usually carried out at 30 to 40°C for 15 to 60 hours, with aeration or agitation if necessary. The human LH/hCG receptor protein can be isolated and purified from the culture described above, for example, by the following method. When the human LH/hCG receptor protein is extracted from the cultured cells, the cells are collected by methods known in the art after cultivation. Then, the collected cells are suspended in an appropriate buffer solution and disrupted by ultrasonic treatment, lysozyme and/or freeze-thawing. Thereafter, a crude extracted solution of the human LH/hCG receptor mature peptide is obtained by centrifugation or filtration. The buffer solution may contain a protein denaturant such as urea or guanidine hydrochloride, or a surface-active agent such as Triton® X-100. When the human LH/hCG receptor protein is secreted in the culture solution, a supernatant is separated from the cells by methods known in the art after the conclusion of cultivation, and then collected. The separation and purification of the human LH/hCG receptor contained in the culture supernatant or the extracted solution thus obtained can be performed by an appropriate combination of known separating and purifying methods. The known separating and purifying methods include methods utilizing solubility such as salt precipitation and solvent precipitation, methods mainly utilizing a difference in molecular weight such as dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide gel electrophoresis, methods utilizing a difference in electric charge such as ion-exchange column chromatography, methods utilizing specific affinity such as affinity chromatography, methods utilizing a difference in hydrophobicity such as reverse phase high performance liquid chromatography and methods utilizing a difference in isoelectric point such as isoelectro-focussing electrophoresis. A method may also be used in which an antibody to a fused protein expressed by fusing the human LH/hCG receptor complimentary DNA together with E. coli -derived DNA lacZ is used as an immunoaffinity column. The activity of the human LH/hCG receptor protein thus formed can be measured by an enzyme immunoassay using a specific antibody. The cells transfected or transformed with the cDNA of the present invention can allow the human LH/hCG receptor protein to be produced in large amounts. The human LH/hCG receptor protein produced here is channeled into the study of ovarian physiology, the supply of antibodies to the receptor, the diagnosis and management of ovarian or testicular diseases such as ovulation aberration or oligospermia, and the development of contraceptives. In humans, this TSH receptor can be a target of autoimmune reaction which leads to hyper- or hypo-stimulation of the thyroid gland by autoantibodies in Grave's disease and idiopathic myxedema. The LH/hCG receptor might therefore suppress the LH action in vivo or can conduct hyperstimulation in stead of LH to cause morbidity in the human genital system. The anti-receptor antibody can be detected by producing the receptor by any of the above-described methods, labeling it and examining whether one binding to it (antibody) is present in vivo or not. In addition, it is considered that inhibition of the LH action by an antibody obtained by expressing a portion or all of the receptor cDNA, namely the application of the antibody as a contraceptive, is possible. There have been described above in detail the cloning of the cDNA coding for the human LH/hCG receptor protein, the preparation of the expression vectors for the human LH/hCG receptor protein, the production of the transformants thereby, the production of the human LH/hCG receptor protein by using the transformants and utility thereof. When nucleotides, amino acids and so on are indicated by abbreviations in this specification and drawings, the abbreviations adopted by the IUPAC-IUB Commission on Biochemical Nomenclature or commonly used in the art are employed. For example, the following abbreviations are used. When the amino acids are capable of existing as optical isomers, it is understood that the L-forms are represented unless otherwise specified. DNA : Deoxyribonucleic acid cDNA : Complementary deoxyribonucleic acid A : Adenine T : Thvmine G : Guanine C : Cytosine RNA : Ribonucleic acid mRNA : Messenger ribonucleic acid dATP : Deoxyadenosine triphosphate dTTP : Deoxythymidine triphosphate dGTP : Deoxyguanosine triphosphate dCTP : Deoxycytidine triphosphate ATP : Adenosine triphosphate EDTA : Ethylenediaminetetraacetic acid SDS : Sodium dodecyl sulfate Gly or G : Glycine Ala or A : Alanine Val or V : Valine Leu or L : Leucine Ile or I : Isoleucine Ser or S : Serine Thr or T : Threonine Cys or C : Cysteine Met or M : Methionine Glu or E : Glutamic acid Asp or D : Aspartic acid Lys or K : Lysine Arg or R : Arginine His or H : Histidine Phe or F : Phenylalanine Tyr or Y : Tyrosine Trp or W : Tryptophan Pro or P : Proline Asn or N : Asparagine Gln or Q : Glutamine The precise chemical structure of the human luteinizing hormone-human chorionic gonadotropin receptor proteins of the present invention will depend on a number of factors. Because ionizable amino and carboxyl groups are present in these proteins, a particular protein may be obtained as an acidic or basic salt, or in neutral form. All such preparations which retain their bioactivity when placed in suitable environmental conditions are included in the definition of the receptor proteins of the present invention. Further, the primary amino acid sequence of such proteins may be argumented by derivation using sugar moieties or by other supplementary molecules such as lipids, phosphate and acetyl groups. Such modifications are included in the definition of the receptor proteins of the present invention so long as the bioactivity of the protein is not destroyed. It is expected, of course, that such modifications may quantitatively or qualitatively affect the bioactivity by either enhancing or diminishing the activity of the protein. Further, individual amino acid residues in the chain may be modified by oxidation, reduction, or other derivatization, and the receptor proteins of the present invention may be cleaved to obtain fragments which retain bioactivity. Such alterations which do not destroy bioactivity do not remove such receptor proteins from the definition. Finally modifications to the primary structure itself by deletion, addition, or alteration of the amino acids incorporated into the sequence during translation can be made without destroying the activity of the receptor proteins of the present invention. The present invention will hereinafter be described in more detail with the following Examples. Transformant E. coli JM109/pUC18 obtained in Example 1 described below was deposited with the Fermentation Research Institute, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan (FRI) under the accession number FERM BP-3127 on October 9, 1990. This microorganism was deposited with the Institute for Fermentation, Osaka, Japan (IFO) under the accession number IFO 15096 on October 11, 1990. Transformants E. coli DH1/pHLHR(UEX2) and E. coli JM109/pHLHR(GEX-3X) obtained in Example 2 described below were deposited with the Fermentation Research Institute, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan (FRI) under the accession number FERM BP-3545 and FERM BP-3544 respectively on August 29, 1991. Example 1 (1) Preparation of a Human Ovary-Derived cDNA Library Total RNA was extracted from the human ovary by the guanidine thiocyanate method, and then mRNA was purified by use of an oligo(dt) cellulose column (Type 7, Pharmacia). Using a cDNA synthesizing kit (Pharmacia), cDNA was synthesized from about 2 µg of purified mRNA. The terminus of this cDNA was rendered flush with T4 DNA polymerase, followed by addition of an EcoRI adapter. This cDNA was bound to a λgt10 vector, and in vitro packaging was carried out by use of a packaging kit (Gigapack Gold, Stratagene). This library contained 1X10 6 independent recombinants, and was proliferated. (2) Purification of a Probe A cDNA library was prepared from the rat ovary in a manner similar to that described above, and inserted into a λZaPII vector (Stratagene). A rat LH/hCG receptor was cloned therefrom to isolate clones Zap3-5-1 (2.8 kb). The clones were labeled using the random primer method (Amersham), and used as a probe. (3) Screening A λgt10 cDNA library phage solution of 5X10 4 plaque forming units (pfu) was mixed with 500 µl of C600hfl (cultivated overnight), and the mixture was incubated at 37°C for 15 minutes. Then, 8 ml of 0.75% agarose (Nippon Gene) LB was added thereto, and the mixture was inoculated on a 1.5% agar LB plate (15 cm dish). A nitrocellulose filter (Hybond-N, Amersham) was placed on the plate on which plaques were formed, and DNA was fixed. Subsequently, the filter was prehybridized at 65°C for 1 to 2 hours in a solution prepared by adding 0.1% bovine serum albumin (BSA), polyvinylpyrrolidone, Ficoll® 400 (Pharmacia), 5% pyrophosphoric acid and 0.1% SDS to 6 X SSC (0.15 M NaCl, 0.015 M sodium citrate, pH 7.0). On hybridization, the probe was added to 200,000 cpm/ml as a guide. The filter was washed with 6 X SSC at 42°C for 15 minutes, and subsequently with 0.1 X SSC at 65°C for 10 minutes. Then, the filter was subjected to autoradiography at -70°C. (4) Analysis of DNA Sequence Some clones were identified, and the longest was selected from these clones for sequence analysis. This clone was subcloned into pUC18 (Takara), and E. coli JM109 was transformed with the resulting plasmid to yield transformant E. coli JM109/pUC18 (FERM BP-3127). This transformant was further shaved off stepwise by exonuclease digestion to prepare long to short single stranded DNA fragments. Sequence analysis was carried out by the dideoxy chain terminal method using a 7DEAZA sequencing kit. Electrophoresis was carried out by use of a LKB2010 Macrophor sequencing system. The SDC Genetyx software was used for data analysis. Fig. 1 shows the nucleotide sequence of the DNA of the human LH/hCG receptor protein, as well as the amino acid sequence deduced therefrom. The nucleotide sequence obtained in the present invention has additional 8 DNAs (-8 to -1) prior to N-terminus of the nucleotide sequence of SEQ ID NO:1. Example 2 Expression of human LH/hCG receptor protein (briefly referred to as HLHR protein) (1) The HLHR cDNA clones obtained in Example 1 were used. The lac Z-HLHR fusion gene was obtained by cloning the 1400 bp EcoRI-Xba fragment coding for extracellular segment of the HLHR into the BamHI site of pUEX2. The lac Z-HLHR fusion construction was transformed into E. coli DH1 host to yield transformant E. coli DHl/pHLHR(UEX2) (FERM BP-3545). For preparation of lacZ-HLHR fusion protein, the transformant was cultivated in LB overnight at 30°C. 5 ml of the LB medium was innoculated with 50 µl of the overnight culture. After incubation of 2 h at 30°C with aeration and further incubation of 2 h at 42°C, the cells were pelleted.The pellets were dissolved in a SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer. The solution was subjected to 5% SDS-PAGE. E. coli transformed with pUEX2 vector was similarlly subjected to 5% SDS-PAGE. After electrophoresis, the gel was stained with Coomassie Blue. The result is shown in Fig. 3. Lane 1 shows a molecular weight marker, lane 2 shows the case of pUEX2 vector and lane 3 shows the present transformant. A band at 110 kda of lane 2 disappears and a new band at 159 kda appears. The result of the electrophoresis and analysis of the nucleotide sequence show the expression of HLHR protein. (2) The GST (glutathion S-transferase) -HLHR fusion gene was obtained by cloning the 1400 bp EcoRI-Xba fragment coding for extracellular segment of the HLHR into the BamHI site of pGEX-3X(Pharmacia). The GST-HLHR fusion construction was transformed into E. coli JM 109 host to yield E. coli JM109/pHLHR(GEX-3X) (FERM BP-3544). The transformant was cultivated in LB overnight at 30°C. The overnight culture of JM 109 was diluted 1:10 in 500 ml of fresh medium and cultivated for 1 h at 37°C before adding IPTG to 0.1 mM. After further 7 h culture, the cells were pelleted. The pellets were dissolved in a SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer. The solution was subjected to 10% SDS-PAGE. E. coli transformed with pGEX-3X vector was similarlly subjected to 10% SDS-PAGE. After electrophoresis, the gel was stained with Coomassie Blue. The result is shown in Fig. 4. Lane 1 shows a molecular weight marker, lane 2 shows the case of pGEX-3X vector and lane 3 shows the present transformant. A band at 26 kda of lane 2 disappears and a new band at 75 kda appears. The result of the electrophoresis and analysis of the nucleotide sequence show the expression of HLHR protein. (3) Functional expression of HLHR The expression vector pCHLHR was constructed by introducing the entire coding region of the cloned cDNA and additional flunking regions contained on an RcoRI fragment (2995 bp) into the pCDNA 1 vector. Human kidney 293 cells (ATCC CRL 1573) were maintained in Dulbecco's modified Eagle's medium containing 10% Fetal Calf serum in a humidified atmosphere containing 5% CO 2 . These cells were transiently transfected with pCHLHR, an expression vector encoding for the full-length human LH/hCG receptor, according to the procedure of calcium phosphate-mediated transfection. These cells were tested for their response ability to hCG with an increase in cAMP levels. The result is shown in Fig. 5. In Fig. 5, the points indicate the mean and the bars indicate the range of the data. Sequence Listing SEQ ID NO:1 SEQUENCE LENGTH: 2987 SEQUENCE TYPE: Nucleotide STRANDEDNESS: double TOPOLOGY: Linear MOLECULE TYPE: cDNA to genomic DNA ORIGIN: human ovary SEQUENCE DESCRIPTION:

Claims: A human luteinizing hormone-human chorionic gonadotropin receptor protein, which protein has an amino acid sequence represented by the 1st to 699th amino acid residues of SEQ ID NO:1 or an amino acid sequence lacking the 227th to 289th amino acid residues therefrom or an amino acid sequence represented by the 26th to 699th amino acid residues of SEQ ID NO:1 or an amino acid sequence lacking the 227th to 289th amino acid residues therefrom. A DNA comprising a cDNA sequence coding for human luteinizing hormone-human chorionic gonadotropin receptor protein as defined in claim 1. A DNA claimed in claim 2, in which said cDNA sequence contains a nucleotide sequence represented by the 1st to 2987th nucleotides of SEQ ID NO:1 or a nucleotide sequence lacking the 679th to 866th nucleotides therefrom, or a nucleotide sequence represented by the 76th to 2987th nucleotides of SEQ ID NO:1 or a nucleotide sequence lacking the 679th to 866th nucleotides therefrom. A transformant carrying a DNA as defined in claim 2. The transformant according to claim 4 which is E. coli J. M. 109/pUC18 (FERM BP-3127), wherein the DNA as claimed in claim 4 is subcloned into the vector pUC18. The transformant according to claim 4 which is E. coli DH1/pHLHR(UEX2) (FERM BP-3545). The transformant according to claim 4 which is E. coli JM109/pHLHR(GEX-3X).(FERM BP-3544). A method for preparing a human luteinizing hormone-human chorionic gonadotropin receptor protein as defined in claim 1, which method comprises cultivating a transformant carrying a DNA as defined in claim 2, accumulating the protein in a culture broth, and collecting the same. A pharmaceutical composition comprising an effective amount of a human luteinizing hormone-human chorionic gonadotropin receptor protein as defined in claim 1 and a pharmaceutically acceptable carrier or vehicle. Use of a protein according to claim 1 for preparing a medicament for the diagnosis and management of ovarian and testicular diseases.

Inventors: IGARASHI MASAO, MINEGISHI TAKASHI, NAKAMURA KAZUTO, IGARASHI, MASAO, MINEGISHI, TAKASHI, NAKAMURA, KAZUTO
Applicants: TAKEDA CHEMICAL INDUSTRIES LTD, TAKEDA CHEMICAL INDUSTRIES, LTD.
Application year: 1991
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N1, C12N15